GSK270822A

CAS No. 864082-23-5

GSK270822A( —— )

Catalog No. M34271 CAS No. 864082-23-5

GSK270822A is a selective ROCK1 inhibitor. GSK270822A exhibits IC50 of 9nM, 1100nM, 1550nM for ROCK1, RSK1, p70S6K, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 362 Get Quote
5MG 553 Get Quote
10MG 735 Get Quote
25MG 1076 Get Quote
50MG 1444 Get Quote
100MG 1899 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GSK270822A
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK270822A is a selective ROCK1 inhibitor. GSK270822A exhibits IC50 of 9nM, 1100nM, 1550nM for ROCK1, RSK1, p70S6K, respectively.
  • Description
    Rho-Kinase-IN-3 (compound 12) is a potent and selective Rho kinase (ROCK1) inhibitor with an IC50 value of 8 nM. Rho-Kinase-IN-3 can be used in research of hypertension.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    GRK (GPCRK)
  • Recptor
    GRK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    864082-23-5
  • Formula Weight
    396.44
  • Molecular Formula
    C24H20N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(NC=1C=C2C(=CC1)NN=C2)(=O)C=3C(CC(=O)NC3C)C4=CC5=C(C=C4)C=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Goodman KB, et, al. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem. 2007 Jan 11;50(1):6-9.?
molnova catalog
related products
  • GSK299115A

    GSK299115A (GSK-299115A) is a selective ROCK1 Inhibitor. GSK299115A exhibits IC50 of 8nM, 620nM, 560nM for ROCK1, RSK1, p70S6K, respectively.

  • PEN (human)

    Endogenous peptide GPR83 agonist. ProSAAS-derived neuropeptide.

  • GRK2i

    GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. Corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.